From @AndrewCaravello: 🌕 The Moon Cannot Be Stolen
A message from the cockpit of Slave I, where silence is tracking the signal
Some people need noise to believe progress is happening.
Others mistake $NWBO silence for failure. But in this arena, where law, biology, and precision intertwine, silence is often the surest sign that something disciplined is unfolding.
And when the voices shouting the loudest are the ones asking the wrong questions…
Sometimes the only way to defend the truth
is to say it once, perfectly.
So here’s everything.
No theories. No bravado. Just structure.
📡 Step One: Understanding the Timeline
NWBO submitted its DCVax-L application to the MHRA on December 20, 2023.
But under MHRA accelerated assessment rules, Day 0 doesn’t begin on submission, it starts on the next official cycle date: January 5, 2024.
That means:
Day 90 Ëś April 4
Day 150 Ëś June 3
Day 210 Ëś August 2
MHRA explicitly states:
“Where issues remain at Day 150, a final decision will be made as soon as possible and within 210 clock-on days.”
This is not optional. It is published guidance.
And if MHRA sends a Request for Information (RFI), the clock stops. NWBO replies. Then the clock resumes.
This pause is built into the process and is not publicly disclosed in real time.
So if you’re wondering, “Why no approval yet?”
The answer is:
You’re looking at a clock you don’t know how to read.
📬 NICE Confirms: The Application Is Alive
On July 15, 2025, NICE, the UK authority on pricing and access, responded to a formal inquiry:
“Northwest Biotherapeutics is currently undergoing review by the MHRA. No pricing or reimbursement materials have been submitted. The company has confirmed this directly.”
This confirms five things:
MHRA has not rejected the application
NWBO has not withdrawn
NICE is not involved because the review isn’t done
NWBO is actively communicating with UK authorities
The process is still ongoing
Not theory. Not opinion.
Primary source evidence.
🧠 NWBO Spoke—And Followed Protocol
From NWBO’s March 31, 2025 10-K:
“The MHRA review is underway and is being conducted under the 150-day accelerated review pathway. This review includes several procedural phases, including an initial phase, a clock-stop phase for questions, and a final phase.”
From the June 29, 2024 ASM:
“We will not be providing interim, step-by-step updates. We will simply announce the result when the process concludes.”
This isn’t avoidance.
This is required behavior in the world of tightly regulated biologics.
MHRA does not tolerate loose disclosures.
Sponsors who leak sensitive correspondence jeopardize approval.
So yes, the silence is real.
But it’s not accidental.
It’s by design.
⚖️ SI 2025 No. 87: The Law That Opened the Path
While critics speculated, the UK rewired its legal system.
SI 2025 No. 87 updated the Human Medicines Regulations to create a dedicated framework for named-patient delivery of autologous ATMPs like DCVax-L.
It formally allows:
Delivery of individualized immune therapies to specific patients
Cross-border logistics: tumor tissue in, vaccine out
Use of decentralized, GMP-compliant manufacturing platforms like Flaskworks
Delivery of treatment without NICE and without full marketing authorization
Application of closed-loop, traceable systems licensed under a Control Site
Translation:
Even without formal approval, DCVax-L now has a legal deployment rail in the UK.
This is not theory. It is statutory law.
And DCVax-L fits it like a glove.
🧾 But What About the Critics?
Let’s address the noise directly:
“They burned through 150 days without a decision.”
📌 False. That only works if you ignore MHRA’s actual calendar logic.
📌 False. That assumes no clock-stop, despite NWBO’s 10-K confirming one.
📌 False. That ignores MHRA’s published 210-day allowance.
“Why isn’t NICE involved yet?”
Because they legally can’t be. NICE begins after MHRA issues a decision.
“Why is NWBO so quiet?”
Because they’re following protocol.
Break silence during an active review, and your application can be denied outright.
“What if this means rejection?”
Then why is NICE confirming the application is active?
Why did SI 87 pass, tailored to this delivery model?
Why is NWBO’s disclosure precisely aligned with agency procedure?
Because nothing is broken.
You’re just mistaking structure for delay.
📷 And the Deleted Posts?
Slave I answered all of this. Twice.
Calmly. Directly. Factually.
Both posts were deleted.
So here it is again, archived, visualized, and made bulletproof.
And now we close the loop,
Not with data,
But with clarity.
🪷 The Moon Cannot Be Stolen
Final transmission, from the cockpit of Slave I
Let me tell you a story.
A Zen master lived in a quiet hut.
One night, a thief broke in, hoping to steal something valuable.
But the hut was empty.
There was nothing to take.
The master returned, saw him, and said:
“You’ve come a long way to visit me. Don’t leave empty-handed.”
He removed his robe and handed it to the thief.
The thief fled, stunned.
Then the master sat beneath the moonlight. Alone.
And whispered:
“Poor fellow. I wish I could have given him the moon.”
That’s what this is.
Some come searching for drama.
Some come trying to steal truth they didn’t earn.
And when they find structure instead of scandal, they call it empty.
But the moon is still there.
Brilliant.
Untouched.
High above the noise.
And truth?
It doesn’t need defending.
It only needs to outlast confusion.
So today, from the cockpit of Slave I, I’ll say this:
The process is holding.
The legal rails are live.
The moon has not moved.
And when this story finishes, the light will be undeniable.
Until then:
🛸 Holding orbit on X
📡 Signal: Locked
🌕 The moon cannot be stolen
Han made the Kessel Run in 12 parsecs.
Boba caught him anyway.
NWBO isn’t missing.
It’s just frozen in carbonite
Silent, sealed, and still on target.
And Slave I?
It’s like AI.
It doesn’t shout.
It doesn’t improvise.
It just tracks. Relentless. Exact. Inevitable.
It all depends on who’s flying.
Market Data 
Markets 
AI
